We are currently developing therapies to prevent type 1 diabetes. Three on-going trials are recruiting.
Incretin-based therapy in preclinical Type 1 diabetes in adults (Trial 1): Double-blind, parallel group Randomized controlled trial
The objective is to assess whether daily treatment with GLP-1 analog liraglutide for 6 months in young adult subjects 18-30 years of age and positive for multiple islet autoantibodies
improves endogenous insulin secretion
improves glucose metabolism
induces immunomodulatory or metabolic changes
slows down progression to dysglycemia and overt diabetes
is tolerable and safe
Incretin-based Therapy in Early Diagnosed Type 1 Diabetes: Double-blind, Parallel Group Randomized Controlled Trial
The objective is to assess whether daily treatment with GLP-1 analog liraglutide for 6 months in patients aged 10-30-years, having an early diagnoses of type 1 diabetes (no symptoms, diagnosis in OGTT), and treated with insulin
increases or extends endogenous insulin secretion
reduces the requirement of exogenous insulin
improves blood glucose control
induces immunomodulatory or metabolic changes
is tolerable and safe
Incretin-based therapy in late preclinical Type 1 diabetes (Trial 3): Double-blind, parallel group Randomized controlled trial
The objective is to assess whether daily treatment with GLP-1 analog liraglutide for 6 months in 10-30-year-old subjects with multiple islet autoantibodies and dysglycemia
improves endogenous insulin secretion
reverses dysglycemia
delays progression to clinical type 1 diabetes
induces immunomodulatory or metabolic changes
is tolerable and safe
